Arthritis Clinical Trials in Las Vegas
View 13 new treatments for Arthritis in Las Vegas, NV, and nearby areas, such as Henderson. Every day, Power helps hundreds of arthritis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Las Vegas + 1 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
TG-C for Knee Osteoarthritis
Kolon TissueGene Clinic, Las Vegas + 2 more
This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
David W Romness, MD
Principal Investigator
RTX-GRT7039 Injections for Knee Osteoarthritis
Grünenthal Clinic, North Las Vegas + 3 more
This trial uses knee injections called RTX-GRT7039 for patients with knee osteoarthritis who still have pain despite usual treatments. The injections aim to reduce knee pain, possibly by affecting pain pathways or inflammation.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
RTX-GRT7039 Injection for Osteoarthritis
Grünenthal Clinic, North Las Vegas + 2 more
This trial tests a special injection called RTX-GRT7039 to help reduce knee pain in people with osteoarthritis who still have pain despite usual treatments. The injection works by blocking pain signals from the knee.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Retatrutide for Obesity
Eli Lilly Clinic, Las Vegas + 1 more
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
Study Director
TG-C for Osteoarthritis of the Knee
Kolon TissueGene Clinic, Las Vegas + 1 more
This trial tests TG-C, an injection into the knee, for patients with moderate to severe osteoarthritis. It aims to reduce pain and improve knee function by potentially modifying the disease. TG-C has shown promise in previous studies for managing knee osteoarthritis.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Moon Jong Noh, PhD
Study Chair
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)
Biosplice Clinic, Las Vegas + 1 more
This trial tests a knee injection called lorecivivint for people with severe knee osteoarthritis. The injection aims to reduce pain and improve movement by targeting the painful knee directly. Lorecivivint (LOR) is being tested for its potential to treat osteoarthritis.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Yusuf Yazici, M.D.
Study Director
Pentosan Polysulfate Sodium Injections for Osteoarthritis
Paradigm Biopharmaceuticals Clinic, Las Vegas + 2 more
This trial tests if a new treatment can reduce pain and improve function in people with knee osteoarthritis. The medication aims to reduce inflammation and help repair knee joint damage.Show More
Recruiting
Phase 2 & 3
Est. 3 - 6 Weeks
Thomas Schnitzer
Principal Investigator
GSK3858279 for Osteoarthritis Pain
GlaxoSmithKline Clinic, Henderson + 1 more
This trial is testing a new medication called GSK3858279 to find the best dose for reducing knee pain in people with moderate to severe osteoarthritis. The goal is to determine how much of the medication is needed to be effective and safe. This will help in managing knee pain better for those who suffer from this condition.Show More
Waitlist
Phase 2
Est. 5 - 8 Weeks
GSK Clinical Trials
Study Director
OA-SYS for Osteoarthritis
Ageless Clinic, Las Vegas + 1 more
This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.
Recruiting
No Placebo Trial
Phase 2
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Page 1 of 2
Frequently Asked Questions
Explore related conditions